Related Experiment Video

Updated: Jun 8, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

LHRH-conjugated lytic peptides directly target prostate cancer cells

Clayton Yates1, Starlette Sharp, Jacqueline Jones

  • 1Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USA. cyates@tuskegee.edu

Biochemical Pharmacology
|September 28, 2010
PubMed

Insights

New lytic peptides targeting luteinizing hormone-releasing hormone receptors (LHRH-R) show promise for prostate cancer treatment. These peptides effectively reduced tumor cell growth with minimal toxicity to normal cells, suggesting a potential new therapy.

Area of Science:

  • Oncology
  • Peptide Therapeutics
  • Molecular Targeting

Background:

  • Prostate cancer is a leading cause of male cancer deaths.
  • Limited treatment options exist for hormone-refractory, metastatic prostate cancer.
  • Luteinizing hormone-releasing hormone receptors (LHRH-R) are overexpressed in some prostate cancers.

Purpose of the Study:

  • To design and evaluate novel conjugated lytic peptides targeting LHRH-R for prostate cancer therapy.
  • To assess the efficacy and specificity of these peptides against prostate cancer cell lines.
  • To determine the safety profile of the peptides in normal prostate cells.

Main Methods:

  • Design of two conjugated lytic peptide sequences (JCHLHRH and JC21LHRH) targeting LHRH-R.
  • In vitro testing of peptide efficacy on human prostate cancer cell lines (LNCaP, DU-145, PC-3).
  • Assessment of peptide toxicity on normal primary human prostate epithelial and bone marrow stromal cells.

Main Results:

  • Both JCHLHRH and JC21LHRH demonstrated significant anti-proliferative activity against prostate cancer cell lines.
  • Effective concentrations (IC50) varied by cell line but were in the micromolar range.
  • Peptides showed no toxicity to normal prostate epithelial or bone marrow stromal cells.
  • Morphological changes and reduced cell numbers were observed in PC-3 cells upon peptide exposure.
  • 24-hour peptide exposure blocked PC-3 cell growth for 3 days.

Conclusions:

  • JCHLHRH and JC21LHRH exhibit specific anti-proliferative activity against prostate cancer cells.
  • These peptides possess a favorable safety profile with low toxicity to normal prostate cells.
  • The designed peptides represent a potential novel therapeutic strategy for prostate cancer, particularly hormone-refractory disease.

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...